Novo Nordisk to Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
E! Online on MSN1d
Why Nikki Glaser Is Fiercely Defending OzempicGolden Globes host Nikki Glaser shared why she supports people using the injectable drug Ozempic for weight loss, and also ...
13hon MSN
Ozempic can lead to weight loss; however, intuitive eating advocates believe listening to your body’s hunger signals garner ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
The Bangkok Post on MSN14h
Novo Nordisk Launches Blockchain to Fight Counterfeit DrugsNovo Nordisk Thailand has announced the successful implementation of a blockchain-based traceability solution to verify the ...
Zacks.com on MSN1d
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
In some ways, Ozempic is presented as part of the anti-diet movement, acknowledging that diets don’t work and medication may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback